Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | PAM | P19021 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12836795 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL2508512 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL6041032 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL18218758 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL11127403 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL4749529 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL15799168 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL1361856 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL337170 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL337222 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105463025-B | A kind of bioactivation quantum dot nano carrier is used for the technical method of RNA interference | 广西医科大学 | 2019-10-15 | — | — | CN | claimed |
| CN-109689107-A | Derivatives of amatoxins and their coupling to cell binding molecules | 杭州多禧生物科技有限公司 | 2019-04-26 | — | — | CN | claimed |
| CN-109369853-A | A kind of preparation method of cellulose base elastic material | 王春华 | 2019-02-22 | — | — | CN | claimed |
| CN-108368171-A | AX L-specific antibody-drug conjugates for cancer therapy | 根马布股份公司 | 2018-08-03 | — | — | CN | claimed |
| CN-107677808-A | A kind of immue quantitative detection reagent box of thyroglobulin and preparation method thereof and detection method | 苏州浩欧博生物医药有限公司 | 2018-02-09 | — | — | CN | claimed |
| CN-107074948-A | Antibodies that bind AXL | 根马布股份公司 | 2017-08-18 | — | — | CN | claimed |
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | MEDIBOSTON LIMITED (HK) | 2024-07-09 | — | — | US | disclosed |
| US-11814428-B2 | Anti-PTCRA antibody-drug conjugates and uses thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230277682-A1 | VERRUCARIN A DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230243837-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230137943-A1 | PHOTOPROXIMITY PROFILING OF PROTEIN-PROTEIN INTERACTIONS IN CELLS | THE UNIVERSITY OF CHICAGO | 2023-05-04 | — | — | US | disclosed |
| US-20230057847-A1 | GLP2 RECEPTOR AGONISTS AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2023-02-23 | — | — | US | disclosed |
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| EP-1398327-B1 | Method of producing hydroxyalkyl starch derivatives | FRESENIUS KABI DE GMBH (DE) | 2008-08-27 | — | — | EP | disclosed |
| US-20080096819-A1 | Amino acid substituted molecules | ALLOZYNE, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20070244301-A1 | Pegylated factor VIII | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2007-10-18 | — | — | US | disclosed |
| US-20070042398-A1 | CYANINE DYES AND METHODS OF USE | LI-COR, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20060263886-A1 | Fluorous labeling for selective processing of biologically-derived samples | PETERS ERIC | 2006-11-23 | — | — | US | disclosed |
| EP-1687643-A1 | FLUOROUS LABELING FOR SELECTIVE PROCESSING OF BIOLOGICALLY-DERIVED SAMPLES | IRM, LLC (BM) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005050226-A1 | FLUOROUS LABELING FOR SELECTIVE PROCESSING OF BIOLOGICALLY-DERIVED SAMPLES | IRM LLC (BM) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814428-B2 | Anti-PTCRA antibody-drug conjugates and uses thereof | DCTD, CD2, MCTS1 | KMT2A 394/4885SMN1; SMN2 4086/4885DGKA 1685/4885 |
| US-20230243837-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | KMT2A 4432/4885SMN1; SMN2 3493/4885DGKA 970/4885 |
| US-20080096819-A1 | Amino acid substituted molecules | BCAT2, DNPEP, PTMS | KMT2A 839/4885SMN1; SMN2 4593/4885DGKA 2992/4885 |
| US-20230057847-A1 | GLP2 RECEPTOR AGONISTS AND METHODS OF USE | GLP1R, GIPR, GRPR | KMT2A 3248/4885SMN1; SMN2 1948/4885DGKA 806/4885 |
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | TOP2A, TOP1, XPA | KMT2A 2733/4885SMN1; SMN2 4305/4885DGKA 2746/4885 |
| US-20230277682-A1 | VERRUCARIN A DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | HAVCR2, VARS1, VIM | KMT2A 694/4885SMN1; SMN2 2957/4885DGKA 3683/4885 |
| US-20070042398-A1 | CYANINE DYES AND METHODS OF USE | CRY2, IK, CRY1 | KMT2A 3439/4885SMN1; SMN2 4748/4885DGKA 4310/4885 |
| US-20070244301-A1 | Pegylated factor VIII | F8, F13B, F7 | KMT2A 2568/4885SMN1; SMN2 3032/4885DGKA 1053/4885 |
| US-20230137943-A1 | PHOTOPROXIMITY PROFILING OF PROTEIN-PROTEIN INTERACTIONS IN CELLS | PPIA, S100A4, S100A6 | KMT2A 3560/4885SMN1; SMN2 4690/4885DGKA 3840/4885 |
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | KMT2A 499/4885SMN1; SMN2 3020/4885DGKA 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.